Ovarian cancer is the second most common malignancy of the female genital tract and the most common cause of death from gynecological cancer in the United States. At present, only 20 percent of ovarian cancer patients are diagnosed at localized stage and the majority of patients are diagnosed at advanced stages characterized by poor prognosis. One of the most promising approaches to improved screening and identification of women at risk of ovarian cancer could be the use of serum biological markers. The first biomarker that was proposed for this purpose was an antigenic determinant CA125. However, CA125 as a single measurement detects only about half of the ovarian cancers at Stage I and it may be elevated in benign gynecological conditions. Consequently, CA125 used on a single occasion, as a solitary marker, does not have an adequate sensitivity and specificity as a screening test. We hypothesize that the new strategies involving use of multiple biomarkers can substantially improve the sensitivity and specificity of screening methods for ovarian cancer. With this application, we propose to concentrate on a combination of CA125 with novel promising biomarkers affecting different pathways of ovarian carcinogenesis, which include: lysophosphatidic acid (LPA), a phospholipid growth factor involved in mitogenesis and proliferation of ovarian epithelial cells; and soluble Fas (sFas), a marker of impaired apoptosis, which may lead to formation and persistence of ovarian stroma inclusion cysts and subsequent carcinogenesis. We propose to assess a potential value of the panel of serum biomarkers (CA125, LPA, sFAS) for early detection of ovarian cancer in a case-control study nested within three participating prospective cohorts: the New York University Women's Health Study; the Northern Sweden Health and Disease Study; and the Janus Serum Bank at Oslo University Hospital, Norway.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA096428-02
Application #
6627748
Study Section
Special Emphasis Panel (ZCA1-SRRB-Q (J1))
Program Officer
Silkensen, Shannon M
Project Start
2002-04-20
Project End
2005-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
2
Fiscal Year
2003
Total Cost
$42,198
Indirect Cost
Name
New York University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Linkov, Faina; Gu, Yian; Arslan, Alan A et al. (2009) Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw 20:21-6
Gu, Yian; Zeleniuch-Jacquotte, Anne; Linkov, Faina et al. (2009) Reproducibility of serum cytokines and growth factors. Cytokine 45:44-9
Arslan, Alan A; Gu, Yian; Zeleniuch-Jacquotte, Anne et al. (2008) Reproducibility of serum pituitary hormones in women. Cancer Epidemiol Biomarkers Prev 17:1880-3
Clendenen, Tess V; Arslan, Alan A; Koenig, Karen L et al. (2008) Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett 260:209-15